Imugene

Imugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing HER2 + ve gastric and breast cancer vaccines. The Group's lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.

Contact Details

37 Bligh Street , Suite 1006, Level 10 SYDNEY NSW 2000

info@imugene.com

www.imugene.com

Lists and Charts

Share price

Imugene
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1657^th	Euro Manganese	-64.81%	-23.24%
1658^th	Security Matters	-64.99%	0%
1659^th	Imugene	-65%	-6.89%
1660^th	Arizona Lithium	-65%	14.87%
1661^st	Pantera Minerals	-65.01%	0%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Bradley Glover,	04 Oct 2024
	NEW ROLE: Paul Woodard,	04 Oct 2024
	NEW ROLE: Kim Drapkin, Non-Executive Director	31 Jul 2024
	NEWS: Tagged in Cancer-fighting mission shoots Imugene up ASX boards	13 Nov 2023
	NEW ROLE: Giovanni Selvaggi,	30 Oct 2023
	NEW ROLE: Jakob Dupoint,	30 Oct 2023
	NEWS: Tagged in Healthtech banks on rising numbers	07 Nov 2022
	NEW ROLE: Monil Shah,	23 Sep 2022
	NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear	14 Feb 2022

News Articles

Related Information

Access to our data for Imugene is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Imugene is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today